Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM584T6)

Drug Name

SCH-205831 Drug Info

Synonyms

SCH-205831; CHEMBL371069; SCHEMBL1106195; BDBM50173419; (3R,3aS,4S,4aR,8aS,9aR)-3-Methyl-4-{(E)-2-[5-(3-trifluoromethyl-phenyl)-pyridin-2-yl]-vinyl}-decahydro-naphtho[2,3-c]furan-1-one; (3R,3aS,4S,4aR,8aS,9aR)-3-methyl-4-(2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)-decahydronaphtho[2,3-c]furan-1(3H)-one

Indication

Disease Entry	ICD 11	Status	REF
Thrombosis	DB61-GB90	Investigative	[1]

Cross-matching ID

PubChem CID: 9804049
TTD Drug ID: DM584T6

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Proteinase activated receptor 1 (F2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorapaxar	DMA16BR	Myocardial infarction	BA41-BA43	Approved	[2]
E5555	DMQERC6	Acute coronary syndrome	BA41	Phase 2	[3]
PZ-128	DMU5H3A	Peripheral arterial occlusive disorder	BD4Z	Phase 2	[4]
RWJ-58259	DMYXD6A	Artery stenosis	BD52	Terminated	[5]
FR-171113	DMIQB9E	Thrombosis	DB61-GB90	Terminated	[6]
SCH-602539	DMRDM9S	Arteriosclerosis	BD40	Investigative	[7]
RWJ-56110	DME07AN	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proteinase activated receptor 1 (F2R)	TTL935N	PAR1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Himbacine derived thrombin receptor (PAR-1) antagonists: SAR of the pyridine ring. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4509-13.
2	In Process Citation. Pharm Unserer Zeit. 2009;38(4):320-8.
3	Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation. 2011 May 3;123(17):1843-53.
4	PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2990-3003.
5	RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev. 2003 Winter;21(4):313-26.
6	In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur J Pharmacol. 1999 Nov 19;384(2-3):197-202.
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 347).
8	Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12257-62.